Ozan KOCAKAYA, Erol AVŞAR

HEPATITIS A VACCINES

ISSN: 1019-1941
Yayın Aralığı: 3
Başlangıç: 1988
Yayıncı: Marmara Üniversitesi

As countries prosper, anti-HAV seroprevalance decreases; that is why infection is more commonly encountered in advanced age cases in developed countries. The presence of the risk of developing fulminant hepatitis and the increase in touristic travels to endemic areas, emphasizes the importance of active immunization. Studies for preparing a vaccine started in the late 70's and the first vaccine was introduced in 1992.

PDF

___

Lewis JA. Hepatitis A vaccines. In: Specter S, ed. Viral Hepatitis. Diagnosis. Therapy and Prevention. Totowa, Hew Jersey, Humana Press, 1999;31 7-375.
Clemens R, Safarya A, Hepburn A, et at. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995:171 (Suppl I;)44-49.
Tholen S, Van Damme P, Leentvaar A, et at. The first combined vaccine against hepatitis A and B: an overwiew. Vaccine 1999; 1 7:1657- 1662.
Innis BL, Snitbhan R, Runasal P, et ai. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:1328- 1334.
Van Damme P, Tholen S, Cramm K, et al. Inactivated hepatitis A vaccines: reactogenicity, immunogenicity and long term antibody persistence. J Med Virol I994;44: 446-451.
Lee SD, Chan CY, Yu Ml, et al. Safety and immunogenicity of inactivated hepatitis /I vaccine in patients with chronic liver disease. J Med Virol 1997;52:215-218.